GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARIAD Pharmaceuticals Inc (NAS:ARIA) » Definitions » E10

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) E10 : $-0.86 (As of Sep. 2016)


View and export this data going back to 1994. Start your Free Trial

What is ARIAD Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ARIAD Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2016 was $-0.140. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.86 for the trailing ten years ended in Sep. 2016.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-26), ARIAD Pharmaceuticals's current stock price is $23.99. ARIAD Pharmaceuticals's E10 for the quarter that ended in Sep. 2016 was $-0.86. ARIAD Pharmaceuticals's Shiller PE Ratio of today is .


ARIAD Pharmaceuticals E10 Historical Data

The historical data trend for ARIAD Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARIAD Pharmaceuticals E10 Chart

ARIAD Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.79 -0.83 -0.93 -0.94 -0.95

ARIAD Pharmaceuticals Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.95 -0.95 -0.95 -0.87 -0.86

Competitive Comparison of ARIAD Pharmaceuticals's E10

For the Biotechnology subindustry, ARIAD Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARIAD Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARIAD Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ARIAD Pharmaceuticals's Shiller PE Ratio falls into.



ARIAD Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ARIAD Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2016 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2016 (Change)*Current CPI (Sep. 2016)
=-0.14/101.8610*101.8610
=-0.140

Current CPI (Sep. 2016) = 101.8610.

ARIAD Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
200612 -0.220 85.142 -0.263
200703 -0.230 86.640 -0.270
200706 -0.250 87.906 -0.290
200709 -0.160 87.964 -0.185
200712 -0.230 88.616 -0.264
200803 -0.250 90.090 -0.283
200806 -0.250 92.320 -0.276
200809 -0.290 92.307 -0.320
200812 -0.240 88.697 -0.276
200903 -0.260 89.744 -0.295
200906 -0.240 91.003 -0.269
200909 -0.210 91.120 -0.235
200912 -0.160 91.111 -0.179
201003 -0.210 91.821 -0.233
201006 1.350 91.962 1.495
201009 -0.180 92.162 -0.199
201012 -0.310 92.474 -0.341
201103 -0.290 94.283 -0.313
201106 -0.360 95.235 -0.385
201109 0.100 95.727 0.106
201112 -0.380 95.213 -0.407
201203 -0.350 96.783 -0.368
201206 -0.310 96.819 -0.326
201209 -0.320 97.633 -0.334
201212 -0.360 96.871 -0.379
201303 -0.360 98.209 -0.373
201306 -0.370 98.518 -0.383
201309 -0.360 98.790 -0.371
201312 -0.400 98.326 -0.414
201403 -0.270 99.695 -0.276
201406 -0.300 100.560 -0.304
201409 -0.270 100.428 -0.274
201412 -0.030 99.070 -0.031
201503 -0.280 99.621 -0.286
201506 -0.330 100.684 -0.334
201509 -0.290 100.392 -0.294
201512 -0.320 99.792 -0.327
201603 -0.280 100.470 -0.284
201606 0.560 101.688 0.561
201609 -0.140 101.861 -0.140

Add all the adjusted EPS together and divide 10 will get our e10.


ARIAD Pharmaceuticals  (NAS:ARIA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ARIAD Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Elona Esq. Kogan officer: Sr. V. P. - General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Manmeet Singh Soni officer: EVP, CFO & Treasurer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Timothy P Clackson officer: President, R&D, CSO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Daniel M Bollag officer: Sr. VP, Reg. Affairs & Quality C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Hugh M Cole officer: SVP, Chief Business Officer C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Paris Panayiotopoulos director, officer: President and CEO ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Massimo Radaelli director C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Martin J Duvall officer: EVP, CCO MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437
Frank Haluska officer: SVP, Clinical R&D, CMO C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Headlines

From GuruFocus